土耳其开始生产针对COVID-19的本地版本的favipiravir
每日沙巴与机构
2020年7月14日下午12:24
在COVID-19大流行中，土耳其提高本地生产的“地方和国家”计划又找到了一个利基。
一家政府认可的制药公司
开始生产国内开发的法维吡韦合成药物，该药物根据早期试验发现对冠状病毒有效。
因此，该国将不再需要依靠从中国进口的毒品。
7月10日获得卫生部许可，
综合是一组研究人员的工作
由伊斯坦布尔Medipol大学的副教授MustafaGüzel领导。
生产的第一批产品或10,000箱将捐赠给卫生部，以供土耳其各地的医院使用。
居泽尔（Güzel）在医药研发领域拥有80项专利，他于5年前从美国返回土耳其，在那里他曾为制药业巨人工作多年。
“我们与我的团队日以继夜地工作了40天，并成功地（在国内生产了favipiravir），”
Güzel, who has 80 patents on his name in medicine development, returned to Turkey five years ago from the United States where he worked for pharmaceutical giants for years.
“We worked day and night with my team for 40 days and succeeded (in producing favipiravir domestically),”
Güzel told Demirören News Agency (DHA) on Tuesday.
This is a Japanese-developed drug produced by China.
Turkish firms have long been successful in manufacturing generic drugs but most firms import raw material for production.
At a time of the pandemic,
when imports are limited or canceled, you cannot produce it.
So, for our generic drug, we synthesized the molecules and were able to produce raw material entirely with our own means.
The cooperation between university, public sector and industry enabled this,” he said.
Daily Sabah